We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Encompassing a broad spectrum of conditions, ejaculatory dysfunction (EjD) includes premature ejaculation (PE), anejaculation(AE), and retrograde ejaculation (RE). This chapter discusses the incidence rate, diagnosis methods and treatment options available for treating EjD. Behavioral/psychological treatments, topical anesthetic agents, serotonin reuptake inhibitors (SSRIS) and phosphodiesterase (PDE)-5 inhibitors are the treatment options available for PE. Penile vibratory stimulation, electroejaculation, and surgical sperm extraction from the epididymis or testes are all successful methods for obtaining sperm for later use with ART in AE where the success rates of other methods are low. Common causes of RE can be categorized as anatomic, neurogenic, pharmacological, or idiopathic in origin. Anticholinergics, alpha-adrenergic agonists, or similar combinations may be used to modulate bladder neck activity but are not as effective as imipramine, which should be considered the first-line therapeutic agent for RE.
By
Gaetano Zaccara, Unit of Neurology, Santa Maria Nuova Hospital, Florence, Italy,
Andrea Messori, Drug Information Centre, Careggi Hospital, Florence, Italy,
Massimo Cincotta, Unit of Neurology, Santa Maria Nuova Hospital, Florence, Italy
This chapter discusses the clinical data concerning pharmacodynamic (PD) interactions of antiepileptic drugs (AEDs) with antidepressants (ADs), antipsychotics (APs), central nervous system (CNS) stimulants, anesthetic agents, analgesics and anti-inflammatory drugs. Experimental and clinical data suggest that AEDs and ADs have similar mechanisms of action which could result in favorable and/or unfavorable PD interactions depending on the particular agents involved. AP and AEDs are frequently co-administered and PD interactions concerning their effects on psychosis and seizure threshold are possible. At low doses, stimulants are co-administered with AEDs in the epileptic patient and seem to have beneficial PD interactions. Among anesthetic agents, lidocaine is of particular interest. Treatment of anesthetic-induced convulsions can be particularly difficult because of many possible unfavorable PD interactions. AEDs, analgesics and anti-inflammatory drugs can often be co-administered for the treatment of some forms of pain.